Alvotech gets FDA acceptance for AVT80 BLA review
Alvotech said the FDA accepted for review its biologics license application for AVT80. The company also plans to expand its proposed biosimilar program for Entyvio® to subcutaneous presentations.
Story updates
08:37:18 AM UTC
SquawkNews
Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.